25400212-48de-48a9-96d3-2fc2ee23fd41
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 66
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TNFA_SIGNALING_VIA_NFKB+0.450
- E2F_TARGETS+0.420
- INTERFERON_ALPHA_RESPONSE+0.420
- G2M_CHECKPOINT+0.400
- INFLAMMATORY_RESPONSE+0.380
- INTERFERON_GAMMA_RESPONSE+0.380
- ANGIOGENESIS+0.370
- HYPOXIA+0.370
- MITOTIC_SPINDLE+0.360
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.340
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.460
- MYC_TARGETS_V2-0.380
- BILE_ACID_METABOLISM-0.330
- WNT_BETA_CATENIN_SIGNALING-0.330
- PEROXISOME-0.320
- FATTY_ACID_METABOLISM-0.310
- ADIPOGENESIS-0.260
- MYC_TARGETS_V1-0.250
- XENOBIOTIC_METABOLISM-0.150
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.110
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 270a14bb-8ae5-4372-a66b-b3d71bf217f7 | — | — | 0.816 |
| 2 | SRR650191 | — | — | 0.806 |
| 3 | TCGA-44-7662-01A-11R-2066-07 | — | cohortA1 | 0.797 |
| 4 | MNG751 | — | — | 0.797 |
| 5 | ea0e56e4-d9e3-44a2-9bdb-2e98554f6bff | — | — | 0.782 |
| 6 | C3L-00904 | — | cohortSQ1 | 0.780 |
| 7 | SRR975589 | — | — | 0.766 |
| 8 | SRR8518429 | — | D | 0.765 |
| 9 | 6a43f966-cb2b-47ee-b0f4-c269707daa88 | — | — | 0.761 |
| 10 | SRR8942957 | — | — | 0.761 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 32 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.450 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.420 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.420 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.400 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.380 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.380 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.370 | Remibrutinib | — uncovered |
| HYPOXIA | 0.370 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.360 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.340 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.310 | Inavolisib | — uncovered |
| APOPTOSIS | 0.280 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.250 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.240 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.230 | Inavolisib | — uncovered |
| COMPLEMENT | 0.220 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.180 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.170 | Temsirolimus | — uncovered |
| DNA_REPAIR | 0.160 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.160 | Idelalisib | — uncovered |